Focal Adhesion Kinase Promotes Hepatic Stellate Cell Activation by Regulating Plasma Membrane Localization of TGFβ Receptor 2.
Yunru Chen,Qing Li,Kangsheng Tu,Yuanguo Wang,Xianghu Wang,Dandan Liu,Chen,Donglian Liu,Rendong Yang,Wei Qiu,Ningling Kang
DOI: https://doi.org/10.1002/hep4.1452
2019-01-01
Hepatology Communications
Abstract:Transforming growth factor beta (TGF beta) induces hepatic stellate cell (HSC) differentiation into tumor-promoting myofibroblast, although underlying mechanism remains incompletely understood. Focal adhesion kinase (FAK) is activated in response to TGF beta stimulation, so it transmits TGF beta stimulus to extracellular signal-regulated kinase and P38 mitogen-activated protein kinase signaling. However, it is unknown whether FAK can, in return, modulate TGF beta receptors. In this study, we tested whether FAK phosphorylated TGF beta receptor 2 (TGF beta R2) and regulated TGF beta R2 intracellular trafficking in HSCs. The FAKY397F mutant and PF-573,228 were used to inhibit the kinase activity of FAK, the TGF beta R2 protein level was quantitated by immunoblotting, and HSC differentiation into myofibroblast was assessed by expression of HSC activation markers, alpha-smooth muscle actin, fibronectin, or connective tissue growth factor. We found that targeting FAK kinase activity suppressed the TGF beta R2 protein level, TGF beta 1-induced mothers against decapentaplegic homolog phosphorylation, and myofibroblastic activation of HSCs. At the molecular and cellular level, active FAK (phosphorylated FAK at tyrosine 397) bound to TGF beta R2 and kept TGF beta R2 at the peripheral plasma membrane of HSCs, and it induced TGF beta R2 phosphorylation at tyrosine 336. In contrast, targeting FAK or mutating Y336 to F on TGF beta R2 led to lysosomal sorting and degradation of TGF beta R2. Using RNA sequencing, we identified that the transcripts of 764 TGF beta target genes were influenced by FAK inhibition, and that through FAK, TGF beta 1 stimulated HSCs to produce a panel of tumor-promoting factors, including extracellular matrix remodeling proteins, growth factors and cytokines, and immune checkpoint molecule PD-L1. Functionally, targeting FAK inhibited tumor-promoting effects of HSCs in vitro and in a tumor implantation mouse model. Conclusion: FAK targets TGF beta R2 to the plasma membrane and protects TGF beta R2 from lysosome-mediated degradation, thereby promoting TGF beta-mediated HSC activation. FAK is a target for suppressing HSC activation and the hepatic tumor microenvironment.